KDR and cancer: In 2016, Peng et al. designed and synthesized eighteen N-phenylquinazolin-4- amine hybrids as dual inhibitors of vascular endothelial growth factor receptor 2 (VEGFR-2) and HDACs considering the roles of these receptors in cancer progression (Peng et al., 2016).